Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATG5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATG5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATG5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATG5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATG5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATG5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATG5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATG5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0060491110 | Skin | cSCC | regulation of cell projection assembly | 65/4864 | 188/18723 | 5.34e-03 | 2.69e-02 | 65 |
GO:0120032110 | Skin | cSCC | regulation of plasma membrane bounded cell projection assembly | 64/4864 | 186/18723 | 6.40e-03 | 3.13e-02 | 64 |
GO:001988326 | Skin | cSCC | antigen processing and presentation of endogenous antigen | 13/4864 | 26/18723 | 7.35e-03 | 3.47e-02 | 13 |
GO:005165128 | Skin | cSCC | maintenance of location in cell | 72/4864 | 214/18723 | 7.37e-03 | 3.47e-02 | 72 |
GO:19019845 | Skin | cSCC | negative regulation of protein acetylation | 12/4864 | 24/18723 | 9.91e-03 | 4.35e-02 | 12 |
GO:0016032113 | Thyroid | PTC | viral process | 236/5968 | 415/18723 | 2.48e-26 | 8.24e-24 | 236 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
GO:0022411113 | Thyroid | PTC | cellular component disassembly | 232/5968 | 443/18723 | 1.36e-19 | 1.75e-17 | 232 |
GO:0016236110 | Thyroid | PTC | macroautophagy | 167/5968 | 291/18723 | 1.51e-19 | 1.91e-17 | 167 |
GO:0031396113 | Thyroid | PTC | regulation of protein ubiquitination | 128/5968 | 210/18723 | 3.06e-18 | 3.27e-16 | 128 |
GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0019058113 | Thyroid | PTC | viral life cycle | 167/5968 | 317/18723 | 8.87e-15 | 5.89e-13 | 167 |
GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
GO:0044403113 | Thyroid | PTC | biological process involved in symbiotic interaction | 151/5968 | 290/18723 | 5.83e-13 | 2.85e-11 | 151 |
GO:00183947 | Thyroid | PTC | peptidyl-lysine acetylation | 99/5968 | 169/18723 | 6.54e-13 | 3.08e-11 | 99 |
GO:190300818 | Thyroid | PTC | organelle disassembly | 73/5968 | 114/18723 | 1.60e-12 | 7.12e-11 | 73 |
GO:00064757 | Thyroid | PTC | internal protein amino acid acetylation | 92/5968 | 160/18723 | 1.80e-11 | 7.06e-10 | 92 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATG5 | SNV | Missense_Mutation | | c.286C>G | p.Leu96Val | p.L96V | Q9H1Y0 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
ATG5 | SNV | Missense_Mutation | | c.793C>T | p.Leu265Phe | p.L265F | Q9H1Y0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATG5 | insertion | Frame_Shift_Ins | novel | c.801_802insGGCCTAAGAAGAAAATGGA | p.Ser268GlyfsTer22 | p.S268Gfs*22 | Q9H1Y0 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ATG5 | insertion | In_Frame_Ins | novel | c.799_800insATGAAGCTGAAACCT | p.Ile267delinsAsnGluAlaGluThrPhe | p.I267delinsNEAETF | Q9H1Y0 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ATG5 | deletion | Frame_Shift_Del | novel | c.452delN | p.Lys151SerfsTer65 | p.K151Sfs*65 | Q9H1Y0 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATG5 | SNV | Missense_Mutation | | c.397G>A | p.Asp133Asn | p.D133N | Q9H1Y0 | protein_coding | deleterious(0.03) | probably_damaging(0.919) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATG5 | SNV | Missense_Mutation | | c.32T>C | p.Val11Ala | p.V11A | Q9H1Y0 | protein_coding | deleterious(0) | possibly_damaging(0.83) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATG5 | SNV | Missense_Mutation | | c.793C>A | p.Leu265Ile | p.L265I | Q9H1Y0 | protein_coding | tolerated(0.06) | possibly_damaging(0.609) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATG5 | SNV | Missense_Mutation | | c.16G>T | p.Asp6Tyr | p.D6Y | Q9H1Y0 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATG5 | SNV | Missense_Mutation | | c.688N>A | p.Glu230Lys | p.E230K | Q9H1Y0 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-AA-A017-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |